Skip to main content
. 2020 Jul 1;4(4):269–279. doi: 10.1177/2474126420930863

Figure 1.

Figure 1.

A 72-year-old woman with asymptomatic brolucizumab-associated occlusive retinal vasculopathy in the left eye, noted on routine follow-up 63 days after her third brolucizumab injection. (A) No intraocular inflammation was reported, but occlusion of an inferotemporal arteriole was visible. (B) Fluorescein angiography demonstrated arterial and venous filling defects with associated ischemia in this area, which persisted into the late phase and spared the macula.